Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926018 | 0.85 | IDO1 (0.44) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL17557419 | 0.76 | IDO1 (0.41) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL6927612 | 0.75 | IDO1 (0.42) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL17557418 | 0.75 | IDO1 (0.42) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL14530248 | 0.73 | OPRD1 (0.58) | IDO1TNKSTNKS2SCD | |
| SCHEMBL749252 | 0.73 | OPRD1 (0.58) | AVPR1A | |
| SCHEMBL6927760 | 0.73 | AVPR1A (0.47) | AVPR1APTPN11 | |
| SCHEMBL746096 | 0.71 | GRM2 (0.47) | IDO1TNKSTNKS2SCD | |
| SCHEMBL16404359 | 0.71 | IDO1 (0.40) | IDO1TNKSTNKS2SCDAVPR1A | |
| SCHEMBL747647 | 0.70 | GRM2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2430022-B1 | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | JANSSEN PHARMACEUTICALS INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| WO-2010130424-A9 | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | GRM2, GRM1, GRIA2 | IDO1 1128/4885TNKS 3016/4885TNKS2 2381/4885 |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | FABP3, SLC5A1, SLC5A2 | IDO1 2553/4885TNKS 3728/4885TNKS2 3621/4885 |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | IDO1 995/4885TNKS 3229/4885TNKS2 2697/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | IDO1 1145/4885TNKS 3017/4885TNKS2 2437/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | IDO1 1145/4885TNKS 3017/4885TNKS2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.